← Leaderboards
Yong-Yuan Zhang
Hbvtech
$1,471,296
Attributed
$1,471,296
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $864.9K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,471,296 · 4
By mechanism
N43$912,546 · 2
R43$300,000 · 1
R34$258,750 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsHepatitis B VirusVectorGene TherapyGenesInfectionAntibodiesMapsIn VivoMuscle CellsHiv/HbvHepatitis B InfectionLiverLiver DiseasesAgreementHepatitis B Surface AntigensFoundationsDoseB-LymphocytesBusinessesHepatitis BCellsChronicFace
Grant awards (5)
Evaluating HBVZ10-Based Therapies for cccDNA Clearance: Virological Foundation and Synergistic Combinations$606,178
N43 · FY2025 · AI · contact PI
A development strategy to obtain IND approval of HBVZ10, a new HBV cure therapy candidate$258,750
R34 · FY2025 · AI · contact PI
A New HBV Drug For Establishing Durable Antiviral Efficacy of HBV Treatment$300,000
R43 · FY2021 · AI · contact PI
Development of a Novel HBV Drug$6,500
N43 · FY2021 · AI · contact PI
Development of a Novel HBV Drug$299,868
N43 · FY2020 · AI · contact PI